July 30th 2025
The first-in-class, twice-daily topical formulation is intended for the treatment of non-proliferative diabetic retinopathy and diabetic macular edema.
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
April 17th 2025The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.